# A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis

> **NCT01782339** · PHASE2 · COMPLETED · sponsor: **Barts & The London NHS Trust** · enrollment: 45 (actual)

## Conditions studied

- Germ Cell Tumour

## Interventions

- **DRUG:** Combination Chemotherapy

## Key facts

- **NCT ID:** NCT01782339
- **Lead sponsor:** Barts & The London NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-01
- **Primary completion:** 2021-05-05
- **Final completion:** 2021-05-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782339, "A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01782339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*